198 results on '"Schoder H"'
Search Results
2. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
3. PET‐Adapted Therapy with Nivolumab plus Adriamycin, Vinblastine, and Dacarbazine for Newly Diagnosed Stage III or IV Hodgkin Lymphoma
4. PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DACARBAZINE (N‐AVD) AS FRONTLINE THERAPY IN OLDER ADULTS WITH HODGKIN LYMPHOMA
5. DYNAMICS OF RADIOMIC FEATURES FOLLOWING BRIDGING THERAPY DETERMINE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY OUTCOME
6. Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT).
7. F-18-TFB PET/CT misses intense I-124-avid metastases in prospective comparison in metastatic thyroid cancer
8. Tumor Volume Predicts for Baseline Hypoxia Status in HPV Related Oropharyngeal Carcinomas (OPC) that Underwent Major Radiation De-escalation: The 30 Reduction in Oropharyngeal Cancer Trial
9. Patterns of Relapse and Risk Reduction Following Tumor Debulking by Bridging Radiotherapy prior to Chimeric Antigen Receptor T Cell Therapy in Non-Hodgkin Lymphoma
10. Development and Validation of Diagnostic Interpretation Criteria for Evaluation of F-18 Fluoromisonidazole Hypoxia PET/CT – Inter-Reader Reliability and Accuracy
11. Intra-Treatment Tumor Apparent Diffusion Coefficient, a Quantitative Imaging Metric, is Associated with Neck Nodal Recurrence in De-Escalated Treatment of HPV-Positive Oropharyngeal Cancer (OPC)
12. 1608P Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
13. Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0
14. Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG-PET/CT external beam radiation treatment planning in lung cancer
15. Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0 (vol 49, pg 1386, 2022)
16. Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities
17. CLINICAL OUTCOMES AND THE ROLE OF OBSERVATION IN EARLY‐STAGE FOLLICULAR LYMPHOMA
18. 861P Combined patient specific tumor and HPV sequencing enables high sensitivity detection of ctDNA in HPV-associated oropharyngeal carcinoma patients
19. A comprehensive review of imaging findings in COVID-19 - status in early 2021
20. PO-1583: Non-invasive radiomic imaging prediction of tumour hypoxia: biomarker for FLASH irradiation?
21. Genetic and micro-environmental factors influencing response to definitive 30Gy chemo-radiotherapy (chemoRT) in HPV Positive Oropharyngeal Cancer (OPC)
22. Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences
23. Four-dimensional (4D) PET/CT imaging of the thorax
24. Quantitation of respiratory motion during 4D-PET/CT acquisition
25. ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IMPACTS ON IMMUNE EVASIVE MECHANISMS IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA - A SINGLE CENTER EXPERIENCE
26. Abstract P1-19-03: A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging in patients receiving WBRT with or without sorafenib
27. Phase III Multi-Center, Prospective Randomized Trial Comparing High Dose Single Fraction Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Human Cancer
28. A Personalized Approach Using Hypoxia Resolution to Guide Curative-Intent Radiation Therapy Dose-Reduction to 30 Gy: A Novel De-escalation Paradigm for HPV-Associated Oropharynx Cancers Treated With Concurrent Chemoradiation Therapy
29. A Pilot Study of Cardiac 13 N-Ammonia PET Imaging to Assess Early Cardiotoxicity Following Multibeam Intensity-Modulated Radiation Therapy for Breast Cancer
30. A PHASE I STUDY OF IBRUTINIB COMBINED WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH RELAPSED OR PRIMARY REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
31. PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA
32. THE 23-GENE GENE EXPRESSION-BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL
33. A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED-SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA
34. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
35. [18F]-Fluorocholine Uptake Correlates with Pathologic Evidence of Recurrent Tumor After SRS for Brain Metastases
36. Paediatric bone sarcoma: FDG-PET/CT vs. conventional imaging. A collaborative study
37. Can Metabolic Tumor Volume Further Risk Stratify Patients Eligible for Treatment Deintensification in the Newly Proposed HPV-Associated Oropharyngeal Cancer Staging System?
38. SU‐E‐J‐263: Repeatability of SUV and Texture Parameters in Serial PET Studies
39. Measurement of the branching fractions of the radiative charm decays D^0→K̅ ^(*0) γ and D^0→ϕγ
40. Measurement of the branching fractions of the radiative charm decays D(0)->(K)overbar(*0)gamma and D(0)->phi gamma RID C-5223-2009
41. Measurement of the Branching Fractions of (B)over-bar -> D**l(-)(v)over-bar(l) Decays in Events Tagged by a Fully Reconstructed B Meson RID C-5223-2009
42. Evaluation of Different Methods of 18F-FDG-PET Target Volume Delineation in the Radiotherapy of Head and Neck Cancer
43. Comparison of immediate post-ablation PET/CT and contrast enhanced CT as predictors of local tumor progression within one year of treatment
44. Adnexal mass secondary to extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with associated amyloid deposition
45. HPV-Positive Oropharyngeal Cancers: Midtreatment PET During Radiation Therapy and Implications for Treatment De-escalation
46. Preliminary Results of a Prospective Trial of IMRT Dose De-escalation to Gross Nodal Disease in Human Papillomavirus (HPV)-Positive Oropharyngeal Carcinoma (OPC) Based on Assessment of Tumor Hypoxia Using 18F-FMISO PET Imaging
47. Predictive Modeling of Outcomes Following Definitive Chemoradiation Therapy for Oropharyngeal Cancer Based on FDG-PET Image Characteristics
48. Primary Tumor Metabolic Volume Improves Risk Prediction of Long-term Outcomes in Patients with Oropharyngeal Squamous Cell Carcinoma Treated with Intensity Modulated Radiation Therapy (IMRT) and Chemotherapy
49. Positron Emission Tomography (PET) Response to Initial Chemotherapy and Radiation Therapy (RT) Predicts Local Control in Rhabdomyosarcoma
50. Repeatability of SUV measurements in serial PET
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.